Evidence map›Paper›PMID 26460041›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

A basal stem cell signature identifies aggressive prostate cancer phenotypes.

Bryan A Smith, Artem Sokolov, Vladislav Uzunangelov, Robert Baertsch, Yulia Newton, Kiley Graim, Colleen Mathis, Donghui Cheng, Joshua M Stuart, Owen N Witte

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 1 pooled it
17.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 1 synthesis or guideline pooled it, 199 citations in OpenAlex.

  1. Pooled it
  2. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. RUNX1T1 drives stem-like small-cell neuroendocrine prostate cancer identity.Frontiers in cell and developmental biology · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Carcinogenesis trajectories.Frontiers in cell and developmental biology · 2025
    Article
  17. Article
  18. Review
  19. Enhanced prostatic Esr1The Journal of pathology · 2024
    Article
  20. Article

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Bryan A SmithDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095;
Artem SokolovCenter for Biomolecular Science and Engineering, University of California, Santa Cruz, CA 95064;
Vladislav UzunangelovDepartment of Biomolecular Engineering, University of California, Santa Cruz, CA 95064;
Robert BaertschCenter for Biomolecular Science and Engineering, University of California, Santa Cruz, CA 95064;
Yulia NewtonDepartment of Biomolecular Engineering, University of California, Santa Cruz, CA 95064;
Kiley GraimDepartment of Biomolecular Engineering, University of California, Santa Cruz, CA 95064;
Colleen MathisDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095;
Donghui ChengEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095;
Joshua M StuartCenter for Biomolecular Science and Engineering, University of California, Santa Cruz, CA 95064; Department of Biomolecular Engineering, University of California, Santa Cruz, CA 95064; owenwitte@mednet.ucla.edu jstuart@ucsc.edu.
Owen N WitteDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095; Howard Hughes Medical Institute, University of California, Los Angeles, CA 90095 owenwitte@mednet.ucla.edu jstuart@ucsc.edu.
University of California, Santa Cruz · USUniversity of California, Los Angeles · USBroad Center · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
UCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)U24CA143858 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI BENZ, CHRISTOPHER, HAUSSLER, DAVID H · 2009 to 2016
$8.9M
BIGDATA: Mid-Scale DCM: DA: ESCE: Discovering Molecular ProcessesR01CA180778 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI STUART, JOSHUA MICHAEL · 2013 to 2017
$3.5M
New Integrative Pathway Analysis Methods to Predict Biomedical OutcomesR01GM109031 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI STUART, JOSHUA MICHAEL · 2014 to 2018
$2.9M
Howard Hughes Medical InstituteNCI NIH HHS P30 CA016042NCI NIH HHS R01 CA180778NCI NIH HHS T32 CA009120NCI NIH HHS U24 CA143858NCI NIH HHS U24-CA143858NIGMS NIH HHS R01 GM109031
6 · The paper itself

Abstract

Evidence from numerous cancers suggests that increased aggressiveness is accompanied by up-regulation of signaling pathways and acquisition of properties common to stem cells. It is unclear if different subtypes of late-stage cancer vary in stemness properties and whether or not these subtypes are transcriptionally similar to normal tissue stem cells. We report a gene signature specific for human prostate basal cells that is differentially enriched in various phenotypes of late-stage metastatic prostate cancer. We FACS-purified and transcriptionally profiled basal and luminal epithelial populations from the benign and cancerous regions of primary human prostates. High-throughput RNA sequencing showed the basal population to be defined by genes associated with stem cell signaling programs and invasiveness. Application of a 91-gene basal signature to gene expression datasets from patients with organ-confined or hormone-refractory metastatic prostate cancer revealed that metastatic small cell neuroendocrine carcinoma was molecularly more stem-like than either metastatic adenocarcinoma or organ-confined adenocarcinoma. Bioinformatic analysis of the basal cell and two human small cell gene signatures identified a set of E2F target genes common between prostate small cell neuroendocrine carcinoma and primary prostate basal cells. Taken together, our data suggest that aggressive prostate cancer shares a conserved transcriptional program with normal adult prostate basal stem cells.

Indexed as

Gene Expression ProfilingAntigens, CDEpithelial CellsFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMaleMammary Glands, HumanNeoplasm MetastasisNeuroendocrine TumorsPhenotypeProstatic NeoplasmsProto-Oncogene Proteins c-mycSequence Analysis, RNASignal TransductionAntigens, CDProto-Oncogene Proteins c-mycTranscription Factorsbasal cellneuroendocrine prostate cancerprostate cancerRNA-seqstem cell signature

Identifiers

PMID26460041
PMCPMC4664352
OpenAlexW2162250780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.